Seoul/Washington, D.C.
South Korea’s Samsung Biologics has announced its acquisition of its first U.S.-based drug production facility from GSK for $280 million, marking a significant step in the company’s strategy to meet long-term demand in the U.S. pharmaceutical market. The acquisition will be executed through Samsung Biologics’ U.S. subsidiary, Samsung Biologics America, which will take full ownership of the Rockville, Maryland-based Human Genome Sciences Inc. facility.
The Rockville site currently has a combined 60,000-liter drug substance capacity, and Samsung Biologics has outlined plans for additional investments to expand production capabilities and upgrade technology. The transaction is expected to close by the end of the first quarter of 2026, with the final acquisition value subject to adjustments at that time.
This move aligns with broader trends in the biopharmaceutical sector, as companies such as Celltrion also look to expand drug manufacturing operations in the United States. The acquisition comes amid regulatory and trade considerations, including a U.S.-South Korea agreement capping tariffs on South Korean pharmaceutical imports at 15%, with generic drugs remaining tariff-free.
Samsung Biologics’ stock responded modestly, reflecting a 0.4% decline on the day of the announcement, underperforming the broader market’s 2% gain.
The company’s strategic expansion into the U.S. underscores its commitment to supporting global supply chains and addressing rising demand for contract drug manufacturing in North America.
About Samsung Biologics
Samsung Biologics is a global contract development and manufacturing organization (CDMO) specializing in biopharmaceutical products. With a focus on high-quality, large-scale production, the company serves major pharmaceutical clients worldwide.
About GSK
GSK is a global healthcare company based in the United Kingdom, producing pharmaceuticals, vaccines, and consumer health products. The divestment of the U.S. facility aligns with its strategic focus on core therapeutic areas.
By
